The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.
Research reported in this publication was supported by the NCI of the NIH under Award Number P30CA016056. The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health.
American Cancer Society. Cancer Facts & Figures 2014. Available at: http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf. Accessed October 10, 2016.
Reese AC, Sadetsky N, Carroll PR et al.. Inaccuracies in assignment of clinical stage for localized prostate cancer. Cancer 2011;117:283–289.
Irshad S, Bansal M, Castillo-Martin M et al.. A molecular signature predictive of indolent prostate cancer. Sci Transl Med 2013;5:202ra122.
Partin AW, Kattan MW, Subong ENP et al.. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997;277:1445–1451.
Stephenson AJ, Scardino PT, Eastham JA et al.. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005;23:7005–7012.
Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499.
Swanson GP, Yu C, Kattan MW et al.. Validation of postoperative nomograms in prostate cancer patients with long-term follow-up. Urology 2011;78:105–109.
Bianco FJ Jr, Kattan MW, Scardino PT et al.. Radical prostatectomy nomograms in black American men: accuracy and applicability. J Urol 2003;170:73–77.
Graefen M, Karakiewicz PI, Cagiannos I et al.. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol 2002;20:951–956.
Cho Y, Jung S, Cho N et al.. Impact of international variation of prostate cancer on a predictive nomogram for biochemical recurrence in clinically localised prostate cancer. World J Urol 2014;32:399–405.
Kattan MW, Vickers AJ, Yu C et al.. Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer 2009;115:1005–1010.
Mohler JL, Armstrong AJ, Bahnson RR et al.. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 3, 2016. Accessed March 10, 2015. To view the most recent version of these guidelines, visit NCCN.org.
Fleming ID, Cooper JS, Henson DE et al., eds. AJCC Cancer Staging Manual, 5th edition. New Philadelphia, PA: Lippincott Raven Publishers; 1997.
Harrell FE, Lee KL, Mark DB. Tutorial in biostatistics: multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361–387.
Thompson I, Thrasher JB, Aus G et al.. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177:2106–2131.
Mohler JL, Armstrong AJ, Bahnson RR et al.. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10:1081–1087.
Heidenreich A, Bastian PJ, Bellmunt J et al.. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013. Eur Urol 2014;65:124–137.